跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LIBTAYO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
LIBTAYO
Authorized
STANDARD
LIBTAYO
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
7ccf1eeabc0e02de
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
7ccf1eeabc0e02de
Drug Approval Canada Name
LIBTAYO
Product Name
LIBTAYO
Status
Cancelled Post Market
Status Date
2023-12-08
Original Market Date
2019-05-24
Din
02487152
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FF06 CEMIPLIMAB
Atc Name
l 01 ff 06
Aig Number
0161350001
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
CEMIPLIMAB
250 MG / 5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
7ccf1eeabc0e02de
Type
Standard
Back to Health Canada Approvals